Vogt 1976.
Methods | Setting: USA, hospital outpatient clinic Length of intervention period: 4 weeks Randomisation: yes, method not stated Allocation concealment: unclear Design: parallel group Masking: double blind Excluded: not stated Withdrawals: stated Baseline characteristics: comparable (but no data to support) Jadad score: 3 | |
Participants | 93 adolescents/adults: 33M 60F Age range: 14 to 65 years Inclusion criteria: Patients with reversible airways disease (not further defined) requiring continuous use of inhaled bronchodilators, but not requiring oral steroids 15% or greater improvement in FEV1 following inhaled isoproteronol Exclusion criteria: Not stated | |
Interventions | BDP: 100 mcg 2 pfs 4x daily (800mcg/d) Placebo: 2 pfs 4xdaily Delivery device: MDI |
|
Outcomes | FEV1 FVC FEF25t o 75 8 am plasma cortisol Extent of symptom relief score Aerosol evaluation score physicians and patients Withdrawal due to asthma exacerbation (number of patients) Oro‐pharyngeal side effects | |
Notes | Reply from author but unable to clarify method use of allocation concealment. | |
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Allocation concealment? | Unclear risk | B ‐ Unclear |